Myriad Genetics Secures $200M Credit Facility
Myriad Genetics secured a five-year, $200 million senior secured term loan from OrbiMed, replacing its previous asset-based lending (ABL)...
Immuthera and Poltreg Secure FDA Nod for T1D Trial
The FDA has signaled its acceptance of PolTREG’s existing clinical data in Stage 3 Type 1 diabetes (T1D) as...
UCLA Health Joins Briacell’s Pivotal Breast Cancer Study
BriaCell Therapeutics has added UCLA Health Jonsson Comprehensive Cancer Center as a clinical site for its ongoing Phase 3...
Real-world Leqembi® Study Data at AAIC 2025
Real-world data from 178 early Alzheimer’s disease (AD) patients treated with lecanemab show an 87.4% treatment continuation rate at...
Trethera Gets FDA Clearance for TRE-515 Clinical Trial
The FDA has cleared Trethera Corporation to initiate a clinical trial evaluating TRE-515 in healthy volunteers. This trial will...
Progyny Study Reveals Gap in Women’s Health Benefit Perceptions
A Progyny-Dynata survey of 1,202 women and 252 benefits decision-makers at large US companies reveals a stark disconnect between...
Arbor Biotechnologies Doses First Patient in ABO-101 Gene Editing Study
Arbor Biotechnologies has dosed the first patient in its Phase 1/2 rephine trial of ABO-101, a CRISPR gene editing...
Tenaya Gene Therapies Advance to Clinical Trials Following Positive Safety Reviews
Tenaya Therapeutics announced positive recommendations from independent Data Safety Monitoring Boards (DSMBs) for its two cardiovascular gene therapy trials:...
New Amsterdam Pharma’s Broadway Trial Shows Positive Alzheimer’s Biomarker Reductions
NewAmsterdam Pharma’s cholesteryl ester transfer protein (CETP) inhibitor, obicetrapib, significantly reduced plasma p-tau217 levels, a key Alzheimer’s disease biomarker,...
Vyne Announces Mixed Phase 2b Results for Repibresib Gel in Vitiligo
VYNE Therapeutics’ Phase 2b trial of Repibresib gel for nonsegmental vitiligo failed to meet its primary endpoint of F-VASI50...